Oncology · Hodgkin LymphomaTrial Updateclinicalmid-term

Magrolimab and Pembrolizumab Combination Study in Hodgkin Lymphoma Initiated

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/6/2026, 6:02:39 AM

Assessment confidence: 85% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of this clinical trial for magrolimab and pembrolizumab in Hodgkin lymphoma is significant as it may introduce a new treatment option in a competitive market. Positive outcomes could enhance the therapeutic landscape and influence treatment guidelines, impacting market dynamics. Regulatory context from FDA (FDA AP — KEYTRUDA (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (22 high-relevance).

Strategic Assessment

Portfolio teams should monitor the trial's progress as positive results could enhance the therapeutic offerings and market positioning of both magrolimab and pembrolizumab. The strongest clinical anchor is Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma (ClinicalTrials.gov), entity match (merck sharp dohme llc); patient population match (refractory). In Oncology · Hodgkin Lymphoma, 6 regulatory and 6 competitive items passed relevance filtering for Merck Sharp & Dohme LLC.

Competitive Pressure

The most relevant competitive pressure comes from BrainChild Bio Initiates CAR T Therapy Study for DIPG Patients (Humanexa Signals) — mechanism alignment (io ); sponsor/company relevance (merck). Secondary pressure from Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC).

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — KEYTRUDA (SUPPL) (FDA). Entity match (pembrolizumab); Regulatory pathway relevance (bla). The trial's outcomes may affect future regulatory approvals and labeling for both drugs, depending on the efficacy and safety demonstrated in the study.

Key Risks

Elevated medium regulatory exposure for Merck Sharp & Dohme LLC could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful trial results could lead to increased market share for both magrolimab and pembrolizumab, potentially altering competitive positioning in the Hodgkin lymphoma treatment space.
Lead sponsor: Ranjana Advani. Collaborators: Merck Sharp & Dohme LLC. The purpose of this study is to test the safety and efficacy of magrolimab in combination with pembrolizumab in patients with Hodgkin lymphoma.
Lead sponsor: AstraZeneca. This is Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).
Upside for Merck Sharp & Dohme LLC may improve if A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC).

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results and overall trial outcomes, which could influence treatment guidelines and competitive dynamics.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — KEYTRUDA (SUPPL)
FDAhigh relevance
Entity match (pembrolizumab); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — KEYTRUDA QLEX (SUPPL)
FDAhigh relevance
Entity match (pembrolizumab); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — KEYTRUDA QLEX (SUPPL)
FDAhigh relevance
Entity match (pembrolizumab); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — KEYTRUDA (SUPPL)
FDAhigh relevance
Entity match (pembrolizumab); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — KEYTRUDA QLEX (SUPPL)
FDAhigh relevance
Entity match (pembrolizumab); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — WELIREG (SUPPL)
FDAhigh relevance
Sponsor/company relevance (Merck); Regulatory pathway relevance (nda)
FDA document
View source

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Entity match (merck sharp dohme llc); Patient population match (refractory)
FDA document
View source
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca); Patient population match (refractory)
FDA document
View source
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck); Patient population match (refractory)
FDA document
View source
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Ritu
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck); Patient population match (refractory)
FDA document
View source
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck); Patient population match (refractory)
FDA document
View source
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Propor
ClinicalTrials.govhigh relevance
Entity match (merck sharp dohme llc)
FDA document
View source
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
ClinicalTrials.govhigh relevance
Entity match (merck sharp dohme llc)
FDA document
View source
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
ClinicalTrials.govhigh relevance
Entity match (merck sharp dohme llc)
FDA document
View source

BrainChild Bio Initiates CAR T Therapy Study for DIPG Patients
Humanexa Signalshigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (Merck)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Merck)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Merck)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Merck)

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedhigh relevance
Entity match (pembrolizumab)
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Safety and immunogenicity of COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase
PubMedhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Post-activation performance enhancement (PAPE) and taurine combination improves anaerobic performance in highly trained wrestlers: a double-blind, randomized, crossover study.
PubMedhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Merck Sharp & Dohme LLC
Magrolimab
Pembrolizumab

Commercial impact

medium

Successful trial results could lead to increased market share for both magrolimab and pembrolizumab, potentially altering competitive positioning in the Hodgkin lymphoma treatment space.

Regulatory impact

medium

The trial's outcomes may affect future regulatory approvals and labeling for both drugs, depending on the efficacy and safety demonstrated in the study.

What to watch

Key milestones include interim results and overall trial outcomes, which could influence treatment guidelines and competitive dynamics.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.